Not all of the identified genetic abnormalities in NSCLC (KRAS, SOX2, CDKN2A, and TP53) are currently targetable by small molecule inhibitors or monoclonal antibodies [11, 13, 28]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.